We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| RAPT Therapeutics Inc | NASDAQ:RAPT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.00 | 4.00 | 4.15 | 166 | 12:00:00 |
From May 2023 to May 2024
Poster presentation details:
| Title: | Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon)plus pembrolizumab in subjects with non-small cell lung cancer not previouslytreated with checkpoint inhibitor |
| Abstract Number: | 629-C |
| Date & Time: | Friday, November 3, 2023; 9:00 a.m. – 7:00 p.m. PT |
| Location: | Exhibit Hall B – San Diego Convention Center |
| Title: | Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and incombination with pembrolizumab in advanced cancer |
| Abstract Number: | 704 |
| Date & Time: | Saturday, November 4, 2023; 9:00 a.m. – 8:30 p.m. PT |
| Location: | Exhibit Halls A and B1 – San Diego Convention Center |
The full abstracts will be released to the public on Tuesday, October 31, 2023 at 9:00 a.m. ET in a Journal for ImmunoTherapy of Cancer (JITC) supplement.
About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The Company is also pursuing a range of targets that are in the discovery stage of development.
Investor Contact:Sylvia Wheelerswheeler@wheelhouselsa.com
Media Contact:Aljanae Reynoldsareynolds@wheelhouselsa.com
1 Year RAPT Therapeutics Chart |
1 Month RAPT Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
